Phio pharmaceuticals fintel

Author: qabw

August undefined, 2024

WebbPHIO Stock Financial Analysis - Phio Pharmaceuticals Corp (NASDAQ) Stock. Fintel ... WebbPHIO / Phio Pharmaceuticals Corp off-exchange short sale volume is shown in the following chart. Short Sale volume shows the number of trades marked as short sales in …

PHIO SEC Filings - Phio Pharmaceuticals Corp - Annual Report, …

WebbPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update. Additional Formats PDF Version. February 22, 2024 Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer. Additional Formats PDF Version. February 13, 2024 ... Webb359 rader · Phio Pharmaceuticals Corp insider trades are shown in the following chart. Insiders are officers, directors, or significant investors in a company. In general, it is … blacklist release date season 9

PHIO / Phio Pharmaceuticals Corp - Institutional Ownership - fintel.io

Webb10 apr. 2024 · Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. About the company Risk Analysis Earnings have declined by 8.5% per year over past 5 years Has less than 1 year of cash runway Makes less than USD$1m in revenue ($0) Does not have a meaningful market cap ($7M) + 2 more risks See All Risk Checks … WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAI technology makes immune cells more effective in … WebbPHIO Institutional Ownership, Sellers - Phio Pharmaceuticals Corp. Fintel ... blacklist renewal

Acciones Phio Pharma Cotización NASDAQ:PHIO hoy

Phio pharmaceuticals fintel

WebbAll rights reserved. Fintel® is a registered trademark. Privacy Policy; Terms and Conditions; This website is provided “as is” without any representations or warranties, express or … Webb1 mars 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic...

Did you know?

WebbPhio Pharmaceuticals Contact Us Contact Us Get in touch with us. General inquiries: [email protected] Investor relations information: [email protected] Employment opportunities: [email protected] Business development inquiries: [email protected] 257 Simarano Dr Marlborough, MA 01752 Webb6 apr. 2024 · Phio Pharmaceuticals (NASDAQ:PHIO) has a recorded net income of -$11.48 million. PHIO has generated -$10.68 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Call Transcripts …

WebbPHIO / Phio Pharmaceuticals Corp Implied Volatility - Fintel Labs. Fintel ... WebbPhio Pharmaceuticals Corp. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 (508) 767-3861 February 7, 2024 VIA EDGAR Securities and Exchange Commission Division of …

WebbPHIO - Phio Pharmaceuticals Corp. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. × publish chart save to portfolio create alert compare perf. Candle - advanced Intraday Daily Weekly Monthly Draw Fullscreen Settings PHIO - Stock Price Chart PHIO [NASD] Webb2024-11-14 - BlackRock Inc. has filed a 13F-HR form disclosing ownership of 19 shares of Phio Pharmaceuticals Corp (US:PHIO) with total holdings valued at $0 USD as of 2024 …

WebbPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in …

Webb22 feb. 2024 · Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™)... blacklist renewed 2023WebbThe average one-year price target for Phio Pharmaceuticals is $73.44 The forecasts range from a low of $72.72 to a high of $75.60. Update Frequency: Monthly PHIO / Phio … blacklist removal service for iphoneWebbPhio Pharmaceuticals Corp (NASDAQ:PHIO) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in … blacklist renewed 2022WebbAt Phio Pharmaceuticals, our mission is to develop innovative cancer treatments that overcome tumor immunosuppression and weaponize the immune system against … gap band charlie wilsonWebbDeutsche Bank Ag\ closes position in PHIO / Phio Pharmaceuticals Corp Institutional Ownership: 13F and NPORT Filings The Security and Class in the table below are shown … gap band discography wikipediaWebb8 apr. 2024 · MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO ), a clinical stage biotechnology company developing the next generation of therapeutics based on... blacklist renewed or cancelledWebbFör 1 dag sedan · PHIO PHARMACEUTICALS CORP. : Financial news and information Stock PHIO PHARMACEUTICALS CORP. Nasdaq: PHIO Nasdaq PHIO PHARMACEUTICALS CORP. : Financial news and information Stock PHIO PHARMACEUTICALS CORP. Nasdaq: PHIO Nasdaq PHIO PHARMACEUTICALS CORP. … gap band charlie wilson raleigh tour